Trident Brands Inc - Quarter Report: 2019 February (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X]
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2019
|
Commission file number 000-53707
TRIDENT BRANDS INCORPORATED
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
200 South Executive Drive, Suite 101
Brookfield, WI 53005
(Address of principal executive offices, including zip code.)
(262) 789-6689
(Telephone number, including area code)
Resident Agents of Nevada
711 S. Carson Street, Suite 4
Carson City, NV 89701
(Name and Address of Agent for Service)
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES [X] NO [
]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES [X] NO [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of "large accelerated filer, "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[ ]
|
Non-accelerated filer
|
[X]
|
Smaller reporting company
|
[X]
|
Emerging growth company | [ ] |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES [ ] NO [X]
The number of the registrant’s common shares outstanding as of April 22, 2019
was 32,311,887.
TRIDENT BRANDS INCORORATED
FORM 10-Q
For the quarterly period ended February 28, 2019
TABLE OF CONTENTS
PART I
|
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial Statements (Unaudited)
|
7 |
Consolidated Balance Sheets as at February 28, 2019 and November 30, 2018
|
8 | |
Consolidated Statements of Operations for the three months ended February 28, 2019 and 2018
|
9 | |
Consolidated Statements of Changes in Stockholders' Deficit for the three months ended February 28, 2019 and 2018 | 10 | |
Consolidated Statements of Cash Flows for the three months ended February 28, 2019 and 2018
|
11 | |
Notes to Consolidated Financial Statements
|
12 | |
Item 2
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
17 |
Item 3
|
Quantitative and Qualitative Disclosures about Market Risk
|
21 |
Item 4
|
Controls and Procedures
|
21 |
PART II
|
OTHER INFORMATION
|
|
Item 6
|
Exhibits
|
23 |
2
Basis of Presentation
Except where the context otherwise requires, all references in this Quarterly Report on Form 10-Q (“Form 10-Q”) to the
“Company”, “we”, “us”, “our”, “Trident” and “Trident Brands” or similar words and phrases are to Trident Brands Incorporated and its subsidiaries, taken together.
In this report, all currency amounts are expressed in thousands of United States (“U.S.”) dollars (“$”), except per share
data, unless otherwise stated. Amounts expressed in other than U.S. dollars are noted accordingly. For example, amounts if expressed in Canadian dollars are expressed in thousands of Canadian dollars and preceded by the symbol “Cdn $”.
Forward-Looking
Statements
This Form 10-Q contains forward-looking statements which are based on our current expectations and assumptions and involve
a number of risks and uncertainties. Generally, forward-looking statements do not relate strictly to historical or current facts and are typically accompanied by words such as “anticipate”, “estimate”, “intend”, “project”, “potential”, “continue”,
“believe”, “expect”, “could”, “would”, “should”, “might”, “plan”, “will”, “may”, “predict”, the negatives of such terms, and words and phrases of similar impact and include, but are not limited to references to expected increases in revenues and
margins, growth opportunities, the success of new product launches and line extensions, our ability to finance our business, potential strategic investments, business strategies, competitive strengths, goals, references to key markets where we
operate and the market for our securities. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on certain assumptions
and analyses we make in light of our experience and our interpretation of current conditions, historical trends and expected future developments, as well as other factors that we believe are appropriate in the circumstance.
Whether actual results and developments will agree with our expectations and predictions is subject to many risks and
uncertainties. Accordingly, there are or will be important factors that could cause our actual results to differ materially from our expectations and predictions. We believe these factors include, but are not limited to, the following:
·
|
we have a limited operating history with significant losses and expect losses to continue for the foreseeable
future;
|
·
|
we could face intense competition, which could result in lower revenues and higher expenditures and could
adversely affect our results of operations;
|
·
|
we are governed by only three persons serving as directors and officers which may lead to faulty corporate
governance;
|
·
|
we must attract and maintain key personnel or our business may fail; |
·
|
we may not be able to secure additional financing to meet our future capital needs due to changes in general
economic conditions;
|
·
|
our business and operating results could be harmed if we fail to manage our growth or change;
|
·
|
we have a limited operating history and if we are not successful in growing our business, then we may have to
scale back or even cease our ongoing business operations;
|
·
|
if our intellectual property is not adequately protected, then we may not be able to compete effectively and we
may not be profitable;
|
3
·
|
if we are the subject of an intellectual property infringement claim, the cost of participating in any
litigation could impact our ability to stay in business;
|
·
|
we could lose our competitive advantages if we are not able to protect any of our food and nutritional products
and intellectual property rights against infringement, and any related litigation could be time-consuming and costly;
|
·
|
if we fail to effectively manage our growth our future business results could be harmed and our managerial and
operational resources may be strained;
|
·
|
if we fail to effectively manage our growth our future business results could be harmed and our managerial and
operational resources may be strained;
|
·
|
our services may become obsolete and unmarketable if we are unable to respond adequately to rapidly changing
technology and customer demands;
|
·
|
our failure to appropriately respond to changing consumer preferences and demand for new products or product
enhancements could significantly harm product sales and harm our financial condition and operating results;
|
·
|
if we do not introduce new products or make enhancements to adequately meet the changing needs of our customers,
some of our products could fail in the marketplace, which could negatively impact our revenues, financial condition and operating results;
|
·
|
we are affected by laws and governmental regulations with potential penalties or claims, which could harm our
financial condition and operating results;
|
·
|
since we rely on independent third parties for the manufacture and supply of certain of our products, if these
third parties fail to reliably supply products to us at required levels of quality and which are manufactured in compliance with applicable laws, then our financial condition and operating results would be harmed;
|
·
|
we may incur material product liability claims, which could increase our costs and harm our financial condition
and operating results;
|
·
|
unless we can generate sufficient cash from operations or raise additional funds, we may not be able to meet our
debt obligations;
|
·
|
our customers generally are not obligated to continue purchasing products from us;
|
·
|
if we do not manage our supply chain effectively, our operating results may be adversely affected;
|
·
|
our stock price may be volatile, which may result in losses to our shareholders;
|
·
|
our common shares are thinly traded and our shareholders may be unable to sell at or near ask prices, or at all;
|
·
|
the market price for our common stock is particularly volatile given our status as a relatively small and
developing company, which could lead to wide fluctuations in our share price. Our shareholders may be unable to sell your common stock at or above their purchase price if at all, which may result in substantial losses;
|
4
·
|
we do not anticipate paying any cash dividends to our common shareholders and as a result shareholders may only realize a return when the shares are sold;
|
·
|
we are listed on the OTCQB quotation system and our common stock is subject to “penny stock” rules which could
negatively impact our liquidity and our shareholders’ ability to sell their shares;
|
·
|
volatility in our common share price may subject us to securities litigation;
|
·
|
the elimination of monetary liability against our directors, officers and employees under Nevada law and the
existence of indemnification rights of our directors, officers and employees may result in substantial expenditures by our company and may discourage lawsuits against our directors, officers and employees; and
|
·
|
our business is subject to changing regulations related to corporate governance and public disclosure that have
increased both our costs and the risk of noncompliance.
|
Consequently all forward-looking statements made herein are qualified by these cautionary statements and there can be no
assurance that our actual results or the developments we anticipate will be realized. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this report.
Corporate Legal Structure
and Related Matters
Trident Brands Incorporated has five legal subsidiaries, as detailed below.
Trident Sports Nutrition
Inc. is 100% owned by Trident Brands and is organized to deliver shelf ready product solutions in the active nutrition and dietary supplement segment to leading retailers for private label and control brand programs.
Brain Armor Inc. is
94.8% owned by Trident Brands and is organized to develop, market and sell a portfolio of DHA supplements under the Brain Armor® brand targeted at the cognitive health and performance segment.
Sports Nutrition Product
Inc. (DBA Everlast Nutrition) is 100% owned by Trident Brands and holds an exclusive license to market and sell products in the nutritional food and supplement category under the Everlast® brand.
Trident Brands Canada Ltd.
is 100% owned by Trident Brands Incorporated and holds various banking facilities, and licenses associated with the manufacturing, importation and sale of natural health and nutrition products in Canada.
5
Trident Brands
International Ltd. is 100% owned by Trident Brands and was organized to handle the company’s international operations and sub-license trademarks and/or products in international markets.
The Company’s administrative office is located at 200 South Executive Drive, Suite 101, Brookfield, Wisconsin, 53005 and
its fiscal year end is November 30th.
The Company has authorized capital of 300,000,000 common shares with a par value of $0.001 per share. 32,311,887 common
shares were issued and outstanding as of February 28, 2019 and 32,311,887 as of April 22, 2019.
6
ITEM 1. FINANCIAL
STATEMENTS
The unaudited financial statements for the quarter ended February 28, 2019 immediately follow.
7
TRIDENT BRANDS INCORPORATED
Consolidated Balance Sheets
(Unaudited)
As of
|
As of
|
|||||||
February 28,
|
November 30,
|
|||||||
2019
|
2018
|
|||||||
ASSETS
|
||||||||
Current Assets
|
||||||||
Cash and Cash Equivalents
|
$
|
452,056
|
$
|
3,133,303
|
||||
Accounts Receivable, net of allowance of $5,671 and $32,383 respectively
|
740,836
|
357,492
|
||||||
Inventory
|
1,904,233
|
2,055,063
|
||||||
Prepaid and other current assets
|
167,402
|
123,599
|
||||||
Total Current Assets
|
3,264,527
|
5,669,457
|
||||||
Fixed Assets-Furniture & Fixtures, net
|
29,568
|
31,663
|
||||||
Note Receivable, net of allowance of $617,010 and $617,010, respectively
|
-
|
-
|
||||||
Intangible Assets, net
|
400,000
|
393,580
|
||||||
TOTAL ASSETS
|
$
|
3,694,095
|
$
|
6,094,700
|
||||
LIABILITIES & STOCKHOLDERS' DEFICIT
|
||||||||
Current Liabilities
|
||||||||
Accounts Payable
|
$
|
275,898
|
$
|
1,289,833
|
||||
Accrued Liabilities
|
3,217,733
|
2,994,453
|
||||||
Derivative Liability
|
1,720,098
|
892,000
|
||||||
Total Current Liabilities
|
5,213,729
|
5,176,286
|
||||||
Convertible Debt, net of discount $1,572,972 and $2,082.975, respectively
|
14,127,808
|
13,617,805
|
||||||
Total Liabilities
|
19,341,537
|
18,794,091
|
||||||
Stockholders' Deficit
|
||||||||
Common stock, $0.001 par value, 300,000,000 shares authorized;
|
||||||||
32,311,887
shares issued and outstanding as of February 28, 2019 and November 30, 2018
|
32,312
|
32,312
|
||||||
Additional paid-in capital
|
9,848,636
|
9,564,737
|
||||||
Non-Controlling Interest in Subsidiary
|
(188,375
|
)
|
(170,999
|
)
|
||||
Accumulated Deficit
|
(25,340,015
|
)
|
(22,125,441
|
)
|
||||
Total Stockholders' Deficit
|
(15,647,442
|
)
|
(12,699,391
|
)
|
||||
TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT
|
$
|
3,694,095
|
$
|
6,094,700
|
See Notes to Unaudited Consolidated Financial Statements
8
TRIDENT BRANDS INCORPORATED
Consolidated Statements of Operations
(Unaudited)
Three Months
|
Three Months
|
|||||||
Ended
|
Ended
|
|||||||
February 28,
|
February 28,
|
|||||||
2019
|
2018
|
|||||||
Revenues, net
|
$
|
945,007
|
$
|
1,861,700
|
||||
Cost of Sales
|
610,365
|
1,804,795
|
||||||
Gross Profit
|
334,642
|
56,905
|
||||||
General & Administrative Expenses
|
(1,884,243
|
)
|
(1,644,141
|
)
|
||||
Loss from Operations
|
(1,549,601
|
)
|
(1,587,236
|
)
|
||||
Other Income (Expenses)
|
||||||||
Interest Expense, net
|
(854,251
|
)
|
(463,588
|
)
|
||||
Derivative loss
|
(828,098
|
)
|
-
|
|||||
Total Other Income (Expenses)
|
(1,682,349
|
)
|
(463,588
|
)
|
||||
Net Loss
|
$
|
(3,231,950
|
)
|
$
|
(2,050,824
|
)
|
||
Net loss attributable to Trident
|
(3,214,574
|
)
|
(2,037,195
|
)
|
||||
Net loss attributable to Non-Controlling Interests
|
(17,376
|
)
|
(13,629
|
)
|
||||
Loss per share - Basic and diluted
|
$
|
(0.10
|
)
|
$
|
(0.06
|
)
|
||
Weighted average number of common shares outstanding - Basic and diluted
|
32,311,887
|
32,311,887
|
See Notes to Unaudited Consolidated Financial Statements
9
TRIDENT BRANDS INCORPORATED
Consolidated Statements of Changes in Stockholders' Deficit
For the three months ended February 28, 2019 and 2018
(Unaudited)
Common
|
Additional
|
|||||||||||||||||||||||
Common
|
Stock
|
Paid-in
|
Accumulated | Non-Conrolling | ||||||||||||||||||||
Stock
|
Amount
|
Capital
|
Deficit | Interest | Total | |||||||||||||||||||
Balance, November 30, 2017
|
32,311,887
|
$
|
32,312
|
$
|
7,869,962
|
$
|
(13,751,420
|
)
|
$
|
(124,649
|
)
|
$
|
(5,973,795
|
)
|
||||||||||
Beneficial Conversion Feature on Convertible Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||
Stock Options Expenses
|
-
|
-
|
787,990
|
-
|
-
|
787,990
|
||||||||||||||||||
Net loss, November 30, 2018
|
-
|
-
|
-
|
(2,037,195
|
)
|
(13,629
|
)
|
(2,050,824
|
)
|
|||||||||||||||
Balance, February 28, 2018
|
32,311,887
|
$
|
32,312
|
$
|
8,657,952
|
$
|
(15,788,615
|
)
|
$
|
(138,278
|
)
|
$
|
(7,236,629
|
)
|
||||||||||
Balance, November 30, 2018
|
32,311,887
|
$
|
32,312
|
$
|
9,564,737
|
$
|
(22,125,441
|
)
|
$
|
(170,999
|
)
|
$
|
(12,699,391
|
)
|
||||||||||
Beneficial Conversion Feature on Convertible Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||
Stock Options Expense
|
-
|
-
|
283,899
|
-
|
-
|
283,899
|
||||||||||||||||||
Net loss, November 30, 2018
|
-
|
-
|
-
|
(3,214,574
|
)
|
(17,376
|
)
|
(3,231,950
|
)
|
|||||||||||||||
Balance, February 28, 2019
|
32,311,887
|
$
|
32,312
|
$
|
9,848,636
|
$
|
(25,340,015
|
)
|
$
|
(188,375
|
)
|
$
|
(15,647,442
|
)
|
See Notes to Unaudited Consolidated Financial Statements
10
TRIDENT BRANDS INCORPORATED
Consolidated Statements of Cash Flows
(unaudited)
Three Months
|
Three Months
|
|||||||
Ended
|
Ended
|
|||||||
February 28,
|
February 28,
|
|||||||
2019
|
2018
|
|||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net loss
|
$
|
(3,231,950
|
)
|
$
|
(2,050,824
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Amortization of debt discount
|
510,003
|
262,950
|
||||||
Amortization of license, IP
|
-
|
12,125
|
||||||
Depreciation expense
|
2,095
|
2,096
|
||||||
Derivative Loss
|
828,098
|
|||||||
Stock options expense
|
283,899
|
787,990
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts Receivable
|
(383,344
|
)
|
360,856
|
|||||
Interest Receivable
|
-
|
4,341
|
||||||
Prepaid expenses
|
(43,803
|
)
|
(2,438
|
)
|
||||
Inventory
|
150,830
|
(645,355
|
)
|
|||||
Accounts payable and accrued liabilities
|
(790,655
|
)
|
835,271
|
|||||
Cash used in operating activities
|
(2,674,827
|
)
|
(432,988
|
)
|
||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Additions of Intangible Assets
|
(6,420
|
)
|
(89,050
|
)
|
||||
Cash used in investing activities
|
(6,420
|
)
|
(89,050
|
)
|
||||
Net change in cash and cash equivalents
|
(2,681,247
|
)
|
(522,038
|
)
|
||||
Cash and cash equivalents at beginning of period
|
3,133,303
|
3,143,788
|
||||||
Cash and cash equivalents at end of period
|
$
|
452,056
|
$
|
2,621,750
|
||||
Supplemental disclosure of cash flow information:
|
||||||||
Cash paid for:
|
||||||||
Income taxes
|
$
|
-
|
$
|
-
|
||||
Interest
|
$
|
103,157
|
$
|
-
|
||||
NON-CASH TRANSACTIONS | ||||||||
Unpaid intangible asset acquired
|
$ |
- |
$ |
200,000 |
See Notes to Unaudited Consolidated Financial Statements
11
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
Trident Brands Incorporated (f/k/a Sandfield Ventures Corp.) (“we”, “our”, “the Company”) was incorporated under the laws
of the State of Nevada on November 5, 2007. The Company was formed to engage in the acquisition, exploration and development of natural resource properties.
The Company is now focused on the development of high growth branded and private label consumer products and ingredients
within the nutritional supplement, life sciences and food and beverage categories. The Company is in its early growth stage and has transitioned out of its shell status with the Super-8 filing at the end of August, 2014. Activities to date have
focused on capital formation, organizational development and execution of its branded and private label consumer products and ingredients business plan.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited interim financial statements of Trident Brands Incorporated have been prepared in accordance
with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in
Trident’s Form 10-K filed with SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods
presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the
disclosure contained in the audited financial statements for fiscal 2018 as reported in the Form 10-K have been omitted.
Customer Concentration
The Company had three major customers that accounted for approximately 74.6% and $704,519 of sales for the three month
period ended February 28, 2019 and 76.8% of the accounts receivable compared to one major customer that accounted for 90.5% and $5,116,161 of sales and 59.7% of the accounts receivable for the 12 month period ended November 30, 2018.
Fair Value of
Financial Instruments
The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair
Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date.
Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded
derivatives, marketable securities and listed equities.
Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or
indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including
quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures.
Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can
be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate
swaps, options and collars.
12
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These
inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.
The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term
nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be
available for debt of similar terms which is not significantly different from its stated value. As of February 28, 2019 the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated
balance sheets on a recurring basis, except for a derivative liability, related to the embedded conversion option on the 2018 convertible note, with a fair value as of February 28, 2019 of $1,720,098. The derivative liability was fair valued
using Level 3 inputs.
The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the
derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:
Balance at November 30, 2018
|
$
|
892,000
|
||
Unrealized derivative loss included in other expense
|
828,098
|
|||
Balance at February 28, 2019
|
$
|
1,720,098
|
The fair value of the derivative liabilities are calculated at the time of issuance and the Company records a
derivative liability for the calculated value. Changes in the fair value of the derivative liabilities are recorded in other income (expense) in the consolidated statements of operations.
The following are the assumptions used for derivative instruments valued using the Black Scholes option pricing model as
of February 28, 2019:
Market value of stock on measurement date
|
$
|
0.39
|
||
Risk-fee interest rate
|
2.54
|
%
|
||
Divident yield
|
0
|
%
|
||
Volatility factor
|
99.87
|
%
|
||
Term
|
1.25 yr
|
Revenue Recognition
In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (Topic 606) “Revenue from Contracts with Customers.”
Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605). The new standard’s core principal is that an entity will recognize revenue at an amount that reflects the consideration to which the entity
expects to be entitled in exchange for transferring good or services to a customer. The principles in the standard are applied in five steps: 1) Identify the contract(s) with a customer; 2) Identify the performance obligations in the contract; 3)
Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the entity satisfies a performance obligation. We adopted Topic 606 as of December 1, 2018
using the modified retrospective transition method. The adoption of Topic 606 did not have any material impact on the Company’s consolidated financial statements.
Recent Accounting
Pronouncements
The Company has evaluated the following recent accounting pronouncements through the date the financial statements were
issued and filed with the Securities and Exchange Commission and believe that none of them will have a material effect on the Company’s financial statements:
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting. The amendments
in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual
periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial
statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. This became effective December 1, 2018. The adoption did not have any material impact
on the Company’s consolidated financial statements.
13
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per
Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded
features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the
instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer
would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in
accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded
conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic
260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting
effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this
Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity
early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management’s evaluation was that there was no potential impact to the Company’s
consolidated financial statements.
NOTE 3. LIQUIDITY
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going
concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting
Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise
substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.
As of February 28, 2019, the Company had $452,056 in cash. However, the Company has generated losses and has an
accumulated deficit as of February 28, 2019. The Company completed additional long term financing with the non-US institutional investor, receiving proceeds of $3,400,780 on November 30, 2018 and $2,804,187 on April 13, 2019 through the issuance
of secured convertible promissory notes. The investor has agreed to make additional investments of $3,795,033 ($10,000,000 in the aggregate). Management believes that substantial doubt of our ability to meet our obligations for the next twelve
months from the date these financial statements are issued has been alleviated due to, but not limited to, i) the approval of new financing available to the Company of up to $10,000,000, of which $3,795,033 is still available, ii) anticipated
growth of product sales from our current customer base and new customers, iii) introduction of higher margin products; and iv) controlling of our expenses. We believe that our present and available financial resources will be sufficient to meet
the Company’s obligations and fund our operations at least through the next twelve months from the date these financial statements are issued.
14
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
NOTE 4. WARRANTS AND OPTIONS
On December 6, 2017, our Board of Directors authorized the issuance to its members and management stock options to
purchase up to 2,615,000 share of our common stock. 1,307,500 of the options vest upon issuance and are exercisable for up to five years at $0.85 per share, while the remaining 1,307,500 will vest 12 months following issuance and be exercisable
for up to five years at $1.00 per share. The Options were issued pursuant to the Company’s 2013 Stock Option Plan, which was registered with the Securities and Exchange Commission on Form S-8 in January, 2015. The 2013 Stock Option Plan
authorizes Trident to issue incentive and non-qualified stock options to employees and consultants of the Company to purchase a number of shares not to exceed 15% of the Company’s currently issued and outstanding securities.
On January 4, 2019, our Board of Directors approved the re-pricing of the majority of options previously granted at $0.40
per share.
The total outstanding stock options as of February 28, 2019 are 4,490,000. The Company used the Black-Scholes model to
value the stock options at $1,107,836. For the period ended February 28, 2019, the Company expensed $8,875 as compensation expense compared to $787,990 in the comparable prior year period. The Company also used the Black-Scholes model to value
the re-priced stock options at $275,024 which was also expensed in the period. Following are the assumptions used in the valuation of the re-priced options: Discount rates between 0.90% and 2.10%; Volatility between 85.51% and 79.75%; and with
terms of 2.5 and 3.0 years.
The following table represents stock option activity for the period ended February 28, 2019:
Number of
Options
|
Weighted Average
Exercise Price
|
Contractual Life
in Years
|
Intrinsic
Value
|
|||||||||||||
Outstanding - November 30, 2018
|
4,640,000
|
$
|
1.02
|
2.45
|
||||||||||||
Exercisable - November 30, 2018
|
3,332,500
|
$
|
1.03
|
1.84
|
$ |
-0-
|
||||||||||
Granted
|
-0-
|
|||||||||||||||
Exercised or Vested
|
-0-
|
|||||||||||||||
Forfeited or Expired
|
150,000
|
|||||||||||||||
Outstanding - February 28, 2019
|
4,490,000
|
$
|
1.74
|
2.15
|
||||||||||||
Exercisable - February 28, 2019
|
4,490,000
|
$
|
1.74
|
2.15
|
$
|
-0-
|
All the outstanding warrants have expired as of February 28, 2019.
The following table represents warrant activity for the period ended February 28, 2019:
Number of
Warrants
|
Weighted Average
Exercise Price
|
Contractual Life
in Years
|
Intrinsic
Value
|
|||||||||||||
Outstanding – November 30, 2018
|
225,000
|
$
|
1.35
|
0.20
|
||||||||||||
Exercisable - November 30, 2018
|
-0-
|
|||||||||||||||
Granted
|
-0-
|
|||||||||||||||
Exercised or Vested
|
-0-
|
|||||||||||||||
Cancelled or Expired
|
225,000
|
|||||||||||||||
Outstanding – February 28, 2019
|
-0-
|
$
|
0.0
|
0.00
|
15
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
NOTE 5. RELATED PARTY TRANSACTIONS
The Company neither owns nor leases any real or personal property. The Company is paying a director $750 per month rent
for use of office space and services.
NOTE 6. NOTE RECEIVABLE
On September 12, 2017 the Company entered into a note purchase agreement with Fengate Trident LP (“Fengate”) pursuant to
which, in consideration for the issuance of 811,887 of our common shares to Fengate, we purchased outstanding secured convertible promissory notes of Mycell Technologies LLC having an aggregate balance due and payable of $511,141 in principal and
$94,526 in interest accrued as at September 12, 2017. The purchased notes, which were originally issued to LPF (MCTECH) Investment Corp. on January 22, 2016, February 5, 2016, and May 19, 2016, bear simple interest on unpaid principal at the
rate of ten percent per annum. The outstanding principal and accrued interest is convertible at the option of the note holder into securities of Mycell. The accrued interest as at February 28, 2019 is $105,869. The Company reserved a full
allowance of $617,010 as of February 28, 2019.
NOTE 7. CONVERTIBLE DEBT
On January 29, 2015, the Company entered into a securities purchase agreement with a non-US institutional investor
whereby it agreed to sell an aggregate principal amount of $2,300,000 of senior secured convertible debentures, convertible into shares of the company’s common stock.
The Company received $1,800,000 of the funds from the transaction on February 5, 2015. The balance of $500,000 was
received on May 14, 2015. These convertible notes were subsequently acquired by Fengate on April 28, 2017.
The convertible debentures are convertible into shares of the Company’s common stock at an initial conversion price of
$0.71 per share, for an aggregate of up to 3,239,437 shares. The debentures originally accrued interest at 6% per annum. On September 26, 2016 the Company entered into an amendment agreement related to these convertible debentures whereby the
applicable interest rate was increased from 6% to 8% and provisions added to allow the investor to transfer, sell or hypothecate the convertible notes subject to applicable securities laws. The maturity date of the notes was also extended through
September 30, 2019. We considered ASC Topic 470-50, Debt Modifications and Extinguishments, and determined that the modification was not deemed substantial.
Due to the note being convertible to common shares of the Company, a beneficial conversion feature analysis was
performed. The intrinsic value of the conversion feature was $647,888 which was recognized as debt discount. As of November 30, 2017, the full amount of the debt discount has been amortized.
On September 26, 2016, the Company entered into a securities purchase agreement with a non-US institutional investor,
pursuant to which, in consideration for proceeds of $4,100,000, the Company issued a secured convertible promissory note in the amount of $4,100,000. Pursuant to the securitiespurchase agreement, the investor has agreed, from time to time after
January 1, 2017, to make additional investments at the Company’s request of up to $5,900,000 ($10,000,000 in the aggregate) in one or more tranches of not less than one tranche during any 60 day period. The funding of any tranche under the
agreement (other than the first $4,100,000 which has been funded) is subject to the mutual agreement of the parties as to the use of funds.
On May 9, 2017, the Company received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018 the
third tranche of $1,500,000 for a total investment by the investor of $10,000,000.
The Company used the proceeds of the secured convertible note for general working capital purposes including settlement
of accounts payable and repayment of mature loans.
16
TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
February 28, 2019
(Unaudited)
In consideration of each advance made by the investor pursuant to the securities purchase agreement, the Company issued
to the investor a convertible promissory note of equal value, maturing on September 30, 2019, and bearing interest at the rate of 8% per annum. Each note is secured in first priority against the present and after acquired assets of the Company
and is convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price of $0.60 per share, for an aggregate of up to 16,666,667 shares. These convertible notes were subsequently acquired by
Fengate on April 28, 2017.
Due to the notes being convertible to common shares of the Company, a beneficial conversion feature analysis was
performed. The intrinsic value of the conversion feature of the notes amounted to $3,333,334 and was recognized as a debt discount. As of February 28, 2019, $2,494,950 of the debt discount was amortized to interest of which $352,591 was amortized
during the current three month period compared to $262,950 for the three month period in the prior year. The unamortized discount as of February 28, 2019 is $838,384.
On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement pursuant to which the
Company has agreed to issue to Fengate an additional convertible promissory note (the “2018 Convertible Note”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the 2018
Convertible Note will bear interest at the rate of twelve percent (12%) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September
26, 2016, which forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the average
closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 Convertible Note will mature on November 30, 2019, provided that Fengate may unilaterally postpone the maturity date to
May 31, 2020.
On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780. The 2nd tranche of $2,804,187 will be made available to the Company once certain funding conditions have been met while the balance of $3,795,033 shall be funded and issued
in one or more tranches within 30 days of receipt of written request from the Company.
The Company intends to use the proceeds of the secured convertible note for general working capital purposes including,
without limitation, product development, inventory, and marketing and selling expenses.
The Company analysed the embedded conversion option on the convertible notes for derivative accounting consideration
under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option on the 2018 Convertible Note qualified for derivative accounting. The Company used the Black-Scholes model to value the embedded conversion option at $892,000
on the issuance date of November 30, 2018. The assumptions used were a discount rate of 2.80%, volatility rate of 79.57% and a term of 1.50 years. The Company used the Black-Scholes model to re-value the embedded conversion option at $1,720,098
as of February 28, 2019. The change of $828,098 was recorded as a derivative loss expense. The assumptions used were a discount rate of 2.54%, volatility of 99.87% and a term of 1.25 years. The fair value of the embedded conversion option was
recorded as debt discount and will be amortized over the term of the 2018 Convertible Note. The amortization recognized in the current period was $157,412.
NOTE 8. INTANGIBLE ASSETS
On December 22, 2017, Trident exercised its option under our Exclusive License Agreement (dated March 1, 2015)
to purchase the Brain Armor® brand from DSM Nutrition Products LLC (“DSM”). Subsequently, the parties have executed applicable trademark assignment and purchase agreements necessary to transfer all global intellectual property rights in the Brain
Armor brand to Trident. In lieu of a $400,000USD cash payment to DSM for the value of the Brain Armor® brand as initially intended, the Company agreed to meet certain conditions, that when satisfied will have an equivalent value of $400,000USD.
The costs incurred to meet these conditions are being charged to intangible assets. As of February 28, 2019, the Company has recorded $400,000 of costs to the asset account. Of this amount $200,000 will be paid over time as the Company purchases
omega-3 oil from DSM pursuant to its exclusive supply agreement. During the 3 months ended February 28, 2019, payments of $ 31,680 were made to DSM in connection with this liability and $49,680 in the prior year.
NOTE 9. SUBSEQUENT EVENTS
On March 11, 2019, each convertible note including the 2018 Convertible Note disclosed in Note 9 to the consolidated
financial statements were amended to extend the maturity dates to May 31, 2020.
On April 13, 2019 the Company received the 2nd tranche of funding with proceeds of $2,804,187.
17
ITEM 2. MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
Forward Looking Statements
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”)
should be read in conjunction with the interim consolidated financial statements, and notes thereto, for the quarter ended February 28, 2019 contained under Item 1 of this Quarterly Report on Form 10-Q (“Form 10-Q”) and in conjunction with
the annual consolidated financial statements, and notes thereto, contained in the Annual Report on Form 10-K for the fiscal year ended November 30, 2017 (“Form 10-K”). Unless otherwise indicated herein, the discussion and analysis contained
in this MD&A includes information available to April 22, 2019.
|
Certain statements contained in this MD&A may constitute forward-looking statements as defined under securities
laws. Forward-looking statements may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital
expenditures, financial results, taxes, plans and objectives. In some cases, forward-looking statements can be identified by terms such as “anticipate”, “estimate”, “intend”, “project”, “potential”, “continue”, “believe”, “expect”, “could”,
“would”, “should”, “might”, “plan”, “will”, “may”, “predict”, the negatives of such terms, and other similar expressions concerning matters that are not historical facts. To the extent any forward-looking statements contain future-oriented
financial information or financial outlooks, such information is being provided to enable a reader to assess our financial condition, material changes in our financial condition, our results of operations, and our liquidity and capital
resources. Readers are cautioned that this information may not be appropriate for any other purpose, including investment decisions.
|
Forward-looking statements contained in this MD&A are based on certain factors and assumptions regarding expected
growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Forward-looking statements
are also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors are more fully described in the “Risk Factors” section at Item 1A of the
Form 10-K.
|
Forward-looking statements contained in this commentary are based on our current estimates, expectations and
projections, which we believe are reasonable as of the date of this report. You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. Other than as required under
securities laws, we do not undertake to update any forward-looking information at any particular time.
|
All dollar amounts in this MD&A are
expressed in thousands of U.S. dollars unless otherwise noted.
|
Business Developments
On January 4, 2019 the Company re-priced the majority of all prior options granted to $0.40.
On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement pursuant to which the
Company has agreed to issue to Fengate an additional convertible promissory (the “2018 Convertible Note”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the 2018 Convertible
Note will bear interest at the rate of twelve percent (12%) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September 26, 2016, which
forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the average closing price of the
common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 Convertible Note will mature on November 30, 2019, provided that Fengate may unilaterally postpone the maturity date to May 31, 2020.
On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780.
18
On March 11, 2019, each convertible note including the 2018 Convertible Note disclosed in Note 9 to the consolidated
financial statements were amended to extend the maturity dates to May 31, 2020.
On April 13, 2019 the Company received the 2nd tranche of funding with proceeds of $2,804,187.
The Company intends to use the proceeds of the secured convertible note for general working capital purposes including,
without limitation, product development, inventory, and marketing and selling expenses.
Results of Operations
The following summary of our results of operations should be read in conjunction with our unaudited consolidated financial
statements for the three month periods ended February 28, 2019 and 2018.
Our operating results for three month periods ended February 28, 2019 and 2018 are summarized as follows:
Three Months
Ended
|
Three Months
Ended
|
|||||||
February 28,
|
February 28,
|
|||||||
2019
|
2018
|
|||||||
Revenues
|
$
|
945,007
|
$
|
1,861,700
|
||||
Gross Profit
|
$
|
334,642
|
$
|
56,905
|
||||
Operating Expenses
|
$
|
1,884,243
|
$
|
1,644,141
|
||||
Other Expenses
|
$
|
1,682,349
|
$
|
463,588
|
||||
Net Loss
|
$
|
3,231,950
|
$
|
2,050,824
|
||||
Add back:
|
||||||||
Interest Expense
|
$
|
854,251
|
$
|
463,588
|
||||
Depreciation
|
$
|
2,095
|
$
|
2,096
|
||||
Amortization
|
$
|
-0-
|
$
|
12,125
|
||||
EBITDA
|
(2,375,604
|
)
|
$
|
(1,573,015
|
)
|
Revenues and Gross Profits
Sales in the first quarter of 2019 decreased to $945,007 versus $1,861,700 in the prior period. The decrease was the result
of a commercial shift away from high-volume private label product sales to high-margin branded product sales in the current period. Gross profit increased to $334,642 versus $56,905 with significant margin improvement in the period to 35.4% of
revenues versus 3.1% of revenues in the prior period. This improvement is attributable to strong growth of Brain Armor® and P2N Peak Performance Nutrition® branded products. Management expects revenue and profit contribution improvement as commercial
efforts continue to gain market traction.
Operating Expenses
Our operating expenses for the three month period ended February 28, 2019 and 2018 is summarized below:
Three Months
Ended
February 28,
|
Three Months
Ended
February 28,
|
|||||||
2019
|
2018
|
|||||||
Professional Fees
|
$
|
54,425
|
$
|
38,524
|
||||
General & Administrative Expenses
|
$
|
1,319,644
|
$
|
1,417,264
|
||||
Marketing, Selling & Warehousing Expenses
|
$
|
412,703
|
$
|
108,346
|
||||
Management Salary
|
$
|
39,000
|
$
|
26,000
|
||||
Director's Fees
|
$
|
14,500
|
$
|
22,500
|
||||
Rent
|
$
|
43,971
|
$
|
2,757
|
||||
Royalty
|
$
|
-0-
|
$
|
28,750
|
19
Operating expenses for the three month period ended February28, 2019 were $1,884,243 as compared to $1,644,141 for the
comparative period in 2018, an increase of 14.6%. The increase in our operating expenses was primarily due to an increase in marketing and selling expenses as we roll-out our product offering. These costs are expected to continue to increase
throughout 2019 as we continue to develop and commercialize our product offerings.
Other Expenses
Other expenses for the three month period ended February 28, 2019 increased to $1,682,349 versus $463,588 in the comparative period in
2018. The increase was primarily due to a derivative loss of $828,098 and an increase in interest expense due to higher debt levels and the impact of certain other items including the beneficial conversion feature related to the convertible notes
entered into in 2016, 2017 and 2018.
EBITDA
Reported net loss for the three month period February 28, 2019 was $3,231,950 compared to $2,050,824 in the comparative period in 2018.
After deducting interest, depreciation and amortization, EBITDA for the three month period ended February 28, 2019 was ($2,375,604) compared to ($1,573,015) in 2018. EBITDA included a non-cash option expense of $283,899 for the three month period
February 28, 2019 compared to $787,990 in 2018 and a derivative loss of $828,098.
Balance Sheet Data
The following table provides selected balance sheets data as at February 28, 2019 and February 28, 2018.
Balance Sheet Data:
February 28,
2019
|
February 28,
2018
|
|||||||
Cash and cash equivalents
|
$
|
452,056
|
$
|
2,621,750
|
||||
Total assets
|
$
|
3,694,095
|
$
|
5,570,161
|
||||
Total liabilities
|
$
|
19,341,537
|
$
|
12,986,790
|
||||
Stockholders' (deficit)
|
$
|
(15,647,442
|
)
|
$
|
( 7,236,629
|
)
|
Strategic Orientation
Our objective is to provide our shareholders with solid returns through strategic investments across multiple consumer
product and ingredient platforms. The platforms we are focusing on include:
·
|
Life science technologies and related products that have applications to a range of consumer products;
|
·
|
Nutritional supplements and related consumer goods providing defined benefits to the consumer; and
|
·
|
Functional foods and beverages ingredients with defined health and wellness benefits.
|
We are building our business through strategic investments in high growth early stage consumer brands and
functional ingredient platforms within segment/sectors which we believe offer sustainable commercial potential. We are focused on three core strategies underpinning our objectives:
20
·
|
To execute a multi-tier brand, supply-chain and innovation strategy to drive revenue;
|
·
|
To aggressively manage an asset light business model to drive our low cost platform; and
|
·
|
To drive disciplines leading to increased investor awareness and ability to finance and govern growing operations.
|
While we have yet to achieve profitability, we are making significant progress against our commercial objectives. We
expect revenue and margin to increase as we continue to strengthen distribution partnerships while capitalizing on product innovation, supply-chain optimization and brand equity within our current portfolio.
Liquidity and Capital
Resources
Our cash and cash equivalents balance at February 28, 2019 was $452,056. Management believes the current funds available to
the company will be sufficient to fund our operations for the next twelve months from the date the financial statements are issued.
On January 29, 2015, we entered into a securities purchase agreement with a non-US institutional investor whereby we agreed
to sell an aggregate principal amount of $2,300,000 of senior secured convertible debentures, convertible into shares of the company’s common stock. We received $1,800,000 of the funds from the transaction on February 5, 2015 and the balance of
$500,000 on May 14, 2015. On September 26, 2016, we entered into a Convertible Promissory Note Amendment Agreement with this investor whereby we agreed to extend the maturity date and amend the interest payable on the senior secured convertible
debentures, whereby we extended the term of the notes through September 30, 2019 and interest rate was increased from 6% per annum to 8% per annum. The convertible debentures are convertible into shares of the Company’s common stock at an initial
conversion price of $.71 per share for an aggregate of up to 3,239,437 shares.
On September 26, 2016, we entered into a Securities Purchase Agreement with a non-US institutional investor pursuant to
which, in consideration for proceeds of $4,100,000, we issued a secured convertible promissory note in the amount of $4,100,000. Pursuant to the Securities Purchase Agreement, the investor has agreed, from time to time after January 1, 2017, to make
additional investments at our request of up to $5,900,000 ($10,000,000 in the aggregate) in one or more tranches of not less than one tranche during any 60 day period. The funding of any tranche under the agreement (other than the first $4,100,000
which has been funded) is subject to the mutual agreement of the parties as to the use of funds. The parties have agreed to negotiate in good faith to pre-approve use of funds within 120 days following September 26, 2016. On May 9, 2017, the Company
received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018 the third tranche of funding with proceeds of $1,500,000 for a total investment by the investor of $10,000,000. The Company intends to use the proceeds of the
secured convertible note for general working capital purposes including, without limitation, settlement of accounts payable and repayment of mature loans. In consideration of each advance made by the investor pursuant to the Securities Purchase
Agreement, we will issue to the investor a convertible promissory note of equal value, maturing three years after issuance, and bearing interest at the rate of 8% per annum. Each note will be secured in first priority against the present and after
acquired assets of the Company, and will be convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price per share of $.60, equal to a 25% discount to the 10 day average closing price of the
Company’s common stock for the period immediately preceding the issuance of the applicable note.
On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement pursuant to which the
Company has agreed to issue to Fengate an additional convertible promissory (the “2018 Convertible Note”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the 2018 Convertible
Note will bear interest at the rate of twelve percent (12%) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September 26, 2016, which
forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the average closing price of the
common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 Convertible Note will mature on November 30, 2019, provided that Fengate may unilaterally postpone the maturity date to May 31, 2020.
21
On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780. On April 13, 2019 the
Company received the second tranche of funding with proceeds of $2,804,187. The Company intends to use the proceeds of the secured convertible note for general working capital purposes including, without limitation, product development, inventory,
and marketing and selling expenses.
On March 11, 2019, each convertible note including the 2018 Convertible Note disclosed in Note 9 to the consolidated
financial statements were amended to extend the maturity dates to May 31, 2020.
Off-Balance Sheet
Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on
our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Contractual
Obligations
|
Except for the transactions noted in Business Developments, there have been no material changes outside the normal
course of business in our contractual obligations since January 3, 2015.
|
Critical Accounting
Estimates
|
The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates
and assumptions that affect the reported amounts of assets and liabilities, related revenues and expenses, and disclosure of gain and loss contingencies at the date of the financial statements. The estimates and assumptions made require us
to exercise our judgment and are based on historical experience and various other factors that we believe to be reasonable under the circumstances. We continually evaluate the information that forms the basis of our estimates and assumptions
as our business and the business environment generally changes. The use of estimates is pervasive throughout our financial statements. There have been no material changes to the critical accounting estimates disclosed under the heading
“Critical Accounting Estimates” in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, of the Form 10-K.
|
ITEM 3. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company we are not required to provide this information.
ITEM 4. CONTROLS AND
PROCEDURES
Evaluation of
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and the
principal financial officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of
the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective such that the
material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, recorded, processed, summarized and reported
within the time periods specified in SEC rules and forms relating to our company, particularly during the period when this report was being prepared.
Changes in Internal
Controls Over Financial Reporting
Our management, with the participation of our principal executive officer and principal financial officer have concluded
that there have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter ended February 28, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
22
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS
The following exhibits are included with this quarterly filing:
Exhibit No.
|
Description
|
|
3.1
|
Articles of Incorporation*
|
|
3.2
|
Bylaws*
|
|
31.1
|
Sec. 302 Certification of Chief Executive Officer
|
|
31.2
|
Sec. 302 Certification of Chief Financial Officer
|
|
32.1
|
Sec. 906 Certification of Chief Executive Officer
|
|
32.2
|
Sec. 906 Certification of Chief Financial Officer
|
|
101
|
Interactive data files pursuant to Rule 405 of Regulation S-T.
|
* |
Document is incorporated by reference and can be found in its entirety in our Registration Statement on Form SB-2, SEC File Number 333-148710, at the Securities
and Exchange Commission website at www.sec.gov.
|
23
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
April 22, 2019
|
Trident Brands Incorporated
|
|
/s/ Anthony Pallante
|
||
By: Anthony Pallante
|
||
(Chief Executive Officer & Chair of the Board)
|
||
/s/ Mark Holcombe
|
||
By: Mark Holcombe
|
||
(President, CFO & Director)
|
||
/s/ Scott Chapman
|
||
By: Scott Chapman
|
||
(Director)
|
24